| CONTACTS: |
César García,
Chairman and Chief Executive Officer |
|
818-709-1244
|
|
-or-
|
|
Ron Stabiner, The Wall Street Group, Inc. |
|
212-888-4848 |
CHATSWORTH, CA, June 2, 2008 - Iris Diagnostics, a division of IRIS INTERNATIONAL, INC. (NASDAQ: IRIS),
a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it has earned MedAssets
Supply Chain Systems Gold Vendor Award, one of the highest vendor designations awarded by MedAssets Supply Chain Systems, a MedAssets company (NASDAQ: MDAS). IRIS was recently presented
with the Gold Vendor Award at the MedAssets Healthcare Business Summit in Las Vegas, attended by more than 3,000 healthcare professionals.
The award recognizes outstanding vendors and is based on improving customer savings and customer satisfaction, filing reports and submitting fee schedules
in a timely manner, continuous growth in purchase volume, and supporting MedAssets' philanthropic efforts.
"We are very proud to be recognized by MedAssets Supply Chain Systems for our commitment to excellence in customer service," stated Thomas
Warekois, President of Iris Diagnostics. "This award is a testament to the quality of our products and our employees' determination to provide our customers with excellent
service."
MedAssets Supply Chain Systems offers its customers a full line of IRIS products consisting of the iQ®200 Series of Automated Urine
Microscopy Analyzers and Systems and the iChem™100 Semi-Automated Urine Chemistry Analyzer, as well as consumables, reagents and service agreements.
About MedAssets
MedAssets (NASDAQ: MDAS) partners with healthcare providers to improve their financial strength by implementing integrated spend management and revenue cycle solutions that help control
cost, improve margins and cash flow, increase regulatory compliance, and optimize operational efficiency. MedAssets serves more than 125 health systems, 2,500 hospitals and 30,000
non-acute care healthcare providers. For more information, visit www.medassets.com.
ABOUT IRIS INTERNATIONAL, INC.
IRIS International a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body
fluids. Our products leverage our strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial
applications for our technology have been in the urinalysis market and we are the leading worldwide provider of urine microscopy systems, with an installed based of over 1,800 systems
in over 50 countries.
SAFE HARBOR PROVISION
This press release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, the Company's views on future financial performance, market growth, capital requirements, regulatory developments, new product
introductions and acquisitions, and are generally identified by phrases such as "thinks," "anticipates," "believes," "estimates,"
"expects," "intends," "plans," and similar words. Forward-looking statements are not guarantees of future performance and are inherently subject to
uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. These statements are based upon, among other things,
assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry, R&D initiatives,
competition and capital requirements. Other factors and uncertainties that could affect the Company's forward-looking statements include, among other things, the following:
identification of feasible new product initiatives, management of R&D efforts and the resulting successful development of new products and product platforms; obtaining regulatory
approvals for new and enhanced products; acceptance by customers of the Company's products; integration of acquired businesses; substantial expansion of international sales;
reliance on key suppliers; the potential need for changes in long-term strategy in response to future developments; future advances in diagnostic testing methods and procedures;
potential changes in government regulations and healthcare policies, both of which could adversely affect the economics of the diagnostic testing procedures automated by the
Company's products; rapid technological change in the microelectronics and software industries; and competitive factors, including pricing pressures and the introduction by others
of new products with similar or better functionality than our products. These and other risks are more fully described in the Company's filings with the Securities and Exchange
Commission, including the Company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which should be read in conjunction herewith for a further
discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
